Evidence map›Paper›PMID 28358340›Full record

ReviewMolecules (Basel, Switzerland)2017

Research Progress on

Tiantian Mou, Xianzhong Zhang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Preclinical evaluation of [EJNMMI research · 2024
    Article
  4. Article
  5. Article
  6. Imaging of Chemotherapy-Induced Acute Cardiotoxicity withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tiantian MouDepartment of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. mtt207@163.com.
Xianzhong ZhangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China. zhangxzh@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can absolutely satisfy the demands of clinical practice. In the past decades, tremendous developments happened in the field of

Indexed as

Clinical Trials as TopicCoronary Artery DiseaseFluorine RadioisotopesHumansMyocardial Perfusion ImagingPositron-Emission TomographyRadioactive TracersRadiopharmaceuticalsFluorine RadioisotopesRadioactive TracersRadiopharmaceuticals18F-labeled radiotracerslipophilic cationsmitochondrial complex-1myocardial perfusion imagingpositron emission tomography

Identifiers

PMID28358340
PMCPMC6154634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.